Phospho-CDK9 (Thr186) Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5117216-Each-of-1 | In Stock | ₹ 47,392.50 |
PIPA5117216 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 47,392.50
GST (18%): ₹ 8,530.65
Total Price: ₹ 55,923.15
Antigen
Phospho-CDK9 (Thr186)
Classification
Polyclonal
Conjugate
Unconjugated
Gene
CDK9
Gene Alias
C-2k; CDC2L4; CDC2-related kinase; Cdk9; Cell division cycle 2-like protein kinase 4; Cell division protein kinase 9; CTK1; cyclin dependent kinase 9; cyclin-dependent kinase 9; cyclin-dependent kinase 9 (CDC2-related kinase); PITALRE; RP11-228B15.5; serine/threonine protein kinase PITALRE; Serine/threonine-protein kinase PITALRE; TAK; Tat-associated kinase complex catalytic subunit
Host Species
Rabbit
Purification Method
Affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
1025, 107951, 362110
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Applications
Western Blot
Concentration
0.72 mg/mL
Formulation
PBS with 50% glycerol and 0.01% thimerosal; pH 7.3
Gene Accession No.
P50750, Q641Z4, Q99J95
Gene Symbols
CDK9
Immunogen
A synthetic phosphorylated peptide around T186 of human CDK9 (NP_0012521)
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- Positive Samples: NIH/3T3 Immunogen sequence: RYTNR CDK9 is a serine/threonine kinase which when complexed with CyclinT1 forms an active holoenzyme complex
- This complex plays a key role in regulating the eukaryotic cell cycle
- CDK9 is coexpressed and copurified with CyclinT1
- CDK9 regulates cytokine inducible transcription networks by facilitating promoter recognition of target transcription factors
- CDK9 promotes RNA synthesis in genetic programs for cell growth, differentiation, and viral pathogenesis
- The CDK9/cyclin-K complex also has kinase activity towards CTD of RNAPII and can substitute for CDK9/cyclin-T P-TEFb in vitro
- Chronic activation of CDK9 causes cardiac myocyte enlargement leading to cardiac hypertrophy and confers a predisposition to heart failure.